Oregovomab
Oregovomab (marketed under the trade name OvaRex) is a mouse monoclonal antibody it binds to the antigen CA125, a carbohydrate antigen. It is designed for the treatment of ovarian cancer.[1]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Mouse |
| Target | CA125 |
| Clinical data | |
| Trade names | OvaRex |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Molar mass | ca. 150 kg/mol |
  | |
This drug was developed by AltaRex Corp.
Adverse drug effects
gollark: ***__YAY OVERFORMATTING__***
gollark: The fact that corporations also pay tax does make me wonder who exactly does have to. I thought it was just citizen-shareholders.
gollark: With that v-tag system used for money, you could even invent your own lower-denomination coins!
gollark: Almost certainly.
gollark: I think it's the last bit.
References
- Statement On A Nonproprietary Name Adopted By The USAN Council - Oregovomab, American Medical Association.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.